Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent
暂无分享,去创建一个
H. Fonge | M. Uppalapati | S. Andrahennadi | Anand K. Nambisan | Anjong Florence Tikum | J. Ketchemen | Hanan Babeker | Arunkumar Annan Sudarsan | A. K. Nambisan
[1] Jason S. Lewis,et al. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] N. Gupta,et al. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management , 2021, World journal of gastroenterology.
[3] E. Dadachova,et al. Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma , 2021, Cancers.
[4] M. Abdelrahim,et al. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies , 2021, Biomedicines.
[5] H. Fonge,et al. 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo , 2021, Cancers.
[6] H. Fonge,et al. Production and Semi-Automated Processing of 89Zr Using a Commercially Available TRASIS MiniAiO Module , 2020, Molecules.
[7] Nicholas E. Wojtynek,et al. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer , 2020, Molecular Cancer Therapeutics.
[8] Jason S. Lewis,et al. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. , 2020, Nuclear medicine and biology.
[9] G. Bifulco,et al. Role of biomarkers for early detection of ovarian cancer recurrence. , 2020, Gland surgery.
[10] A. Oza,et al. Epithelial ovarian cancer , 2019, The Lancet.
[11] J. Prehn,et al. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers , 2019, Cancer and Metastasis Reviews.
[12] S. Batra,et al. MUC16 as a novel target for cancer therapy , 2018, Expert opinion on therapeutic targets.
[13] Jason S. Lewis,et al. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. , 2018, Cancer research.
[14] D. Christ,et al. Transient expression of human antibodies in mammalian cells , 2017, Nature Protocols.
[15] G. Scambia,et al. Optimizing treatment in recurrent epithelial ovarian cancer , 2017, Expert review of anticancer therapy.
[16] J. V. van Putten,et al. Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer , 2017, Journal of Innate Immunity.
[17] Xianjun Yu,et al. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma , 2016, Molecular Cancer Research.
[18] Li Li,et al. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer , 2016, Journal of Ovarian Research.
[19] F. Wuest,et al. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis , 2016, The Journal of Nuclear Medicine.
[20] E. Bennett,et al. A novel monoclonal antibody to a defined peptide epitope in MUC16. , 2015, Glycobiology.
[21] Steven M. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.
[22] Anthony P Corfield,et al. Mucins: a biologically relevant glycan barrier in mucosal protection. , 2015, Biochimica et biophysica acta.
[23] Matthew White,et al. In 2014, can we do better than CA125 in the early detection of ovarian cancer? , 2014, World journal of biological chemistry.
[24] Sukjoon Yoon,et al. Somatic Mutaome Profile in Human Cancer Tissues , 2013, Genomics & informatics.
[25] S. Lapi,et al. Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use , 2013, The Journal of Nuclear Medicine.
[26] K. Konstantopoulos,et al. Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation , 2013, Scientific Reports.
[27] Lynn C Francesconi,et al. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. , 2013, Nuclear medicine and biology.
[28] T. Noda,et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma , 2012, Cancer science.
[29] S. Batra,et al. Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type , 2012, Pathobiology.
[30] Judy M. Anderson,et al. Pathobiological Implications of MUC16 Expression in Pancreatic Cancer , 2011, PloS one.
[31] Maxime Pinard,et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. , 2011, Gynecologic oncology.
[32] Mitchell Ho,et al. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy , 2011, Journal of Cancer.
[33] R. Dubridge,et al. The immunogenicity of humanized and fully human antibodies , 2010, mAbs.
[34] D. Kufe,et al. Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.
[35] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[36] H. Koeppen,et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. , 2007, Cancer research.
[37] G. Howard,et al. Making and using antibodies : a practical handbook , 2006 .
[38] Frederic A. Fellouse,et al. Making Antibodies in Bacteria , 2006 .
[39] Mitchell Ho,et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.
[40] R. Michel,et al. Rapid blood clearance of injected mouse IgG2a in SCID mice , 2002, Cancer Immunology, Immunotherapy.
[41] J. Humm,et al. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] P. Buamah. Benign conditions associated with raised serum CA‐125 concentration , 2000, Journal of surgical oncology.
[43] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.